Literature DB >> 29079526

Synergistic enhancement of topotecan-induced cell death by ascorbic acid in human breast MCF-7 tumor cells.

Birandra K Sinha1, Thomas J van 't Erve2, Ashutosh Kumar2, Carl D Bortner3, Ann G Motten2, Ronald P Mason2.   

Abstract

Topotecan, a derivative of camptothecin, is an important anticancer drug for the treatment of various human cancers in the clinic. While the principal mechanism of tumor cell killing by topotecan is due to its interactions with topoisomerase I, other mechanisms, e.g., oxidative stress induced by reactive free radicals, have also been proposed. However, very little is known about how topotecan induces free radical-dependent oxidative stress in tumor cells. In this report we describe the formation of a topotecan radical, catalyzed by a peroxidase-hydrogen peroxide system. While this topotecan radical did not undergo oxidation-reduction with molecular O2, it rapidly reacted with reduced glutathione and cysteine, regenerating topotecan and forming the corresponding glutathiyl and cysteinyl radicals. Ascorbic acid, which produces hydrogen peroxide in tumor cells, significantly increased topotecan cytotoxicity in MCF-7 tumor cells. The presence of ascorbic acid also increased both topoisomerase I-dependent topotecan-induced DNA cleavage complex formation and topotecan-induced DNA double-strand breaks, suggesting that ascorbic acid participated in enhancing DNA damage induced by topotecan and that the enhanced DNA damage is responsible for the synergistic interactions of topotecan and ascorbic acid. Cell death by topotecan and the combination of topotecan and ascorbic acid was predominantly due to necrosis of MCF-7 breast tumor cells. Published by Elsevier Inc.

Entities:  

Keywords:  5, 5-Dimethyl Pyrroline-1-N-oxide; Ascorbic acid; Electron spin resonance; Oxidized glutathione; Reactive oxygen species; Reduced glutathione; Topoisomerase; Topotecan

Mesh:

Substances:

Year:  2017        PMID: 29079526      PMCID: PMC5699936          DOI: 10.1016/j.freeradbiomed.2017.10.377

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  58 in total

1.  Topoisomerase I-DNA complexes contribute to arsenic trioxide-induced apoptosis.

Authors:  Olivier Sordet; ZhiYong Liao; Hong Liu; Smitha Antony; Ellen V Stevens; Glenda Kohlhagen; Haiqing Fu; Yves Pommier
Journal:  J Biol Chem       Date:  2004-06-03       Impact factor: 5.157

2.  Cancer chemotherapy and antioxidants.

Authors:  Kenneth A Conklin
Journal:  J Nutr       Date:  2004-11       Impact factor: 4.798

3.  Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis.

Authors:  Francesca Bruzzese; Monia Rocco; Silvia Castelli; Elena Di Gennaro; Alessandro Desideri; Alfredo Budillon
Journal:  Mol Cancer Ther       Date:  2009-11-03       Impact factor: 6.261

4.  Pro-oxidant and antioxidant mechanisms of etoposide in HL-60 cells: role of myeloperoxidase.

Authors:  V E Kagan; A I Kuzmenko; Y Y Tyurina; A A Shvedova; T Matsura; J C Yalowich
Journal:  Cancer Res       Date:  2001-11-01       Impact factor: 12.701

5.  Reduction of phenoxyl radicals of the antitumour agent etoposide (VP-16) by glutathione and protein sulfhydryls in human leukaemia cells: Implications for cytotoxicity.

Authors:  J C Yalowich; Y Y Tyurina; V A Tyurin; W P Allan; V E Kagan
Journal:  Toxicol In Vitro       Date:  1996-02       Impact factor: 3.500

6.  One- and two-electron oxidation of reduced glutathione by peroxidases.

Authors:  L S Harman; D K Carver; J Schreiber; R P Mason
Journal:  J Biol Chem       Date:  1986-02-05       Impact factor: 5.157

7.  Pharmacological Ascorbate Radiosensitizes Pancreatic Cancer.

Authors:  Juan Du; John A Cieslak; Jessemae L Welsh; Zita A Sibenaller; Bryan G Allen; Brett A Wagner; Amanda L Kalen; Claire M Doskey; Robert K Strother; Anna M Button; Sarah L Mott; Brian Smith; Susan Tsai; James Mezhir; Prabhat C Goswami; Douglas R Spitz; Garry R Buettner; Joseph J Cullen
Journal:  Cancer Res       Date:  2015-06-16       Impact factor: 12.701

8.  Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients.

Authors:  E Jonsson; H Fridborg; P Nygren; R Larsson
Journal:  Eur J Clin Pharmacol       Date:  1998-09       Impact factor: 2.953

9.  High dose concentration administration of ascorbic acid inhibits tumor growth in BALB/C mice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis.

Authors:  Chang-Hwan Yeom; Gunsup Lee; Jin-Hee Park; Jaelim Yu; Seyeon Park; Sang-Yeop Yi; Hye Ree Lee; Young Seon Hong; Joosung Yang; Sukchan Lee
Journal:  J Transl Med       Date:  2009-08-11       Impact factor: 5.531

10.  A review of topotecan in combination chemotherapy for advanced cervical cancer.

Authors:  Minoo Robati; David Holtz; Charles J Dunton
Journal:  Ther Clin Risk Manag       Date:  2008-02       Impact factor: 2.423

View more
  4 in total

1.  Reversal of drug resistance by JS-K and nitric oxide in ABCB1- and ABCG2-expressing multi-drug resistant human tumor cells.

Authors:  Birandra K Sinha; Lalith Perera; Ronald E Cannon
Journal:  Biomed Pharmacother       Date:  2019-10-09       Impact factor: 6.529

Review 2.  High-dose intravenous vitamin C, a promising multi-targeting agent in the treatment of cancer.

Authors:  Franziska Böttger; Andrea Vallés-Martí; Loraine Cahn; Connie R Jimenez
Journal:  J Exp Clin Cancer Res       Date:  2021-10-30

3.  Molecular Mechanisms of Cytotoxicity of NCX4040, the Non-Steroidal Anti-Inflammatory NO-Donor, in Human Ovarian Cancer Cells.

Authors:  Birandra K Sinha; Erik J Tokar; Carl D Bortner
Journal:  Int J Mol Sci       Date:  2022-08-03       Impact factor: 6.208

4.  Efficient Active Oxygen Free Radical Generated in Tumor Cell by Loading-(HCONH₂)·H₂O₂ Delivery Nanosystem with Soft-X-ray Radiotherapy.

Authors:  Lei Xu; Yiran Shao; Chengkang Chang; Yingchun Zhu
Journal:  Materials (Basel)       Date:  2018-04-12       Impact factor: 3.623

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.